Repligen (NASDAQ:RGEN) Director Karen A. Dawes sold 20,000 shares of Repligen stock in a transaction on Friday, May 11th. The stock was sold at an average price of $41.80, for a total value of $836,000.00. Following the sale, the director now owns 114,957 shares of the company’s stock, valued at $4,805,202.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
RGEN stock opened at $42.06 on Friday. The company has a quick ratio of 10.25, a current ratio of 12.22 and a debt-to-equity ratio of 0.17. The stock has a market capitalization of $1.83 billion, a P/E ratio of 60.96, a PEG ratio of 2.78 and a beta of 0.83. Repligen has a 1-year low of $41.65 and a 1-year high of $42.10.
Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, May 8th. The biotechnology company reported $0.17 earnings per share for the quarter, beating the consensus estimate of $0.15 by $0.02. The firm had revenue of $44.80 million during the quarter, compared to the consensus estimate of $43.88 million. Repligen had a return on equity of 6.06% and a net margin of 18.48%. The firm’s quarterly revenue was up 46.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.15 earnings per share. sell-side analysts anticipate that Repligen will post 0.71 EPS for the current fiscal year.
Hedge funds have recently added to or reduced their stakes in the stock. Swiss National Bank raised its holdings in shares of Repligen by 5.3% in the fourth quarter. Swiss National Bank now owns 63,700 shares of the biotechnology company’s stock valued at $2,311,000 after acquiring an additional 3,200 shares in the last quarter. Pier Capital LLC raised its holdings in Repligen by 12.3% in the fourth quarter. Pier Capital LLC now owns 166,195 shares of the biotechnology company’s stock worth $6,030,000 after purchasing an additional 18,256 shares in the last quarter. William Blair Investment Management LLC raised its holdings in Repligen by 70.1% in the fourth quarter. William Blair Investment Management LLC now owns 1,802,569 shares of the biotechnology company’s stock worth $65,397,000 after purchasing an additional 742,634 shares in the last quarter. State of Wisconsin Investment Board raised its holdings in Repligen by 45.0% in the fourth quarter. State of Wisconsin Investment Board now owns 37,700 shares of the biotechnology company’s stock worth $1,368,000 after purchasing an additional 11,700 shares in the last quarter. Finally, Arizona State Retirement System raised its holdings in Repligen by 224.2% in the fourth quarter. Arizona State Retirement System now owns 62,971 shares of the biotechnology company’s stock worth $2,285,000 after purchasing an additional 43,545 shares in the last quarter. Hedge funds and other institutional investors own 87.29% of the company’s stock.
Repligen Company Profile
Repligen Corporation, a bioprocessing company, focuses on the development, manufacture, and commercialization of products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It manufactures and supplies Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins for use in the downstream purification of monoclonal antibodies; and growth factor products used to supplement cell culture media to increase cell growth and productivity in a bioreactor.
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.